[go: up one dir, main page]

EA201270574A1 - Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний - Google Patents

Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний

Info

Publication number
EA201270574A1
EA201270574A1 EA201270574A EA201270574A EA201270574A1 EA 201270574 A1 EA201270574 A1 EA 201270574A1 EA 201270574 A EA201270574 A EA 201270574A EA 201270574 A EA201270574 A EA 201270574A EA 201270574 A1 EA201270574 A1 EA 201270574A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
systems
cardiovascular diseases
rostafuroxin
individual
Prior art date
Application number
EA201270574A
Other languages
English (en)
Inventor
Джузеппе Бьянки
Патриция Феррари
Фабио Маччарди
Original Assignee
Ростакуо С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ростакуо С.П.А. filed Critical Ростакуо С.П.А.
Publication of EA201270574A1 publication Critical patent/EA201270574A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Изобретение предусматривает способы и системы, основанные на влиянии генетической изменчивости (генетических изменений) на биологическую активность, связанную с ростафуроксином, у индивида. В частности, композиции, способы и системы, описанные в настоящей заявке, основаны на выявленном влиянии одного или более полиморфизма в межгенной или внутригенной области гена, выбранной из группы, включающей KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, и ТТС29 и/или генетического изменения в неравновесном сцеплении с ним, на ответ индивида на ростафуроксин.
EA201270574A 2009-10-19 2010-10-18 Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний EA201270574A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25302009P 2009-10-19 2009-10-19
EP09177111 2009-11-25
PCT/EP2010/065589 WO2011048033A2 (en) 2009-10-19 2010-10-18 Methods and systems for pharmacogenomic treatment of cardiovascular conditions

Publications (1)

Publication Number Publication Date
EA201270574A1 true EA201270574A1 (ru) 2012-12-28

Family

ID=41727473

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270574A EA201270574A1 (ru) 2009-10-19 2010-10-18 Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний

Country Status (23)

Country Link
US (1) US9408854B2 (ru)
EP (1) EP2490694B1 (ru)
JP (3) JP2013508329A (ru)
KR (3) KR20120093297A (ru)
CN (1) CN102695512B (ru)
AU (1) AU2010309921B2 (ru)
BR (1) BR112012009144B8 (ru)
CA (1) CA2777310C (ru)
DK (1) DK2490694T3 (ru)
EA (1) EA201270574A1 (ru)
ES (1) ES2551877T3 (ru)
HR (1) HRP20151185T1 (ru)
HU (1) HUE028075T2 (ru)
IL (1) IL219173A (ru)
ME (1) ME02347B (ru)
MX (1) MX2012004559A (ru)
PL (1) PL2490694T3 (ru)
PT (1) PT2490694E (ru)
RS (1) RS54416B1 (ru)
SG (1) SG10201406457VA (ru)
SI (1) SI2490694T1 (ru)
SM (1) SMT201500281B (ru)
WO (1) WO2011048033A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640847A1 (en) * 2010-11-19 2013-09-25 Fondazione Centro San Raffaele del Monte Tabor Markers for acute kidney injury and uses thereof
CN102940640A (zh) * 2012-12-06 2013-02-27 中国生命药物治疗有限公司 罗他夫辛在制备治疗基因缺陷型原发性高血压的药物中的用途
KR102338678B1 (ko) * 2014-04-03 2021-12-13 삼성전자주식회사 항 c-Met 항체 효과 예측을 위한 바이오마커
EP2937421B1 (en) * 2014-04-03 2018-10-24 Samsung Electronics Co., Ltd Biomarker for predicting effect of an anti-C-met antibody
US11761043B2 (en) 2014-05-29 2023-09-19 Geneticure Inc. Machine assay and analysis for selecting antihypertensive drugs
WO2015183938A1 (en) * 2014-05-29 2015-12-03 Geneticure Llc Improved therapeutic regimen for hypertension
EP2977758A1 (en) * 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
CN107447014A (zh) * 2015-01-21 2017-12-08 田小利 Thsd7a基因序列及表达改变检测及其在冠心病预测中的应用
CA3018186C (en) * 2016-03-29 2023-06-13 Regeneron Pharmaceuticals, Inc. Genetic variant-phenotype analysis system and methods of use
CN108728522A (zh) * 2018-06-11 2018-11-02 苏州艾达康医疗科技有限公司 药物基因组检测方法
US11337988B2 (en) 2018-09-27 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ouabain antagonists to inhibit viral infection
US11600375B2 (en) 2021-07-30 2023-03-07 Reviv Global Ltd Genetically personalized food recommendation systems and methods
US11894121B2 (en) 2021-08-06 2024-02-06 Reviv Global Ltd Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001181D0 (en) 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
DE4227616C2 (de) 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
US5632276A (en) 1995-01-27 1997-05-27 Eidelberg; David Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same
SE9501782D0 (sv) 1995-05-12 1995-05-12 Landstinget I Oestergoetland Method of predicting the therapeutic response of a drug against a malignant tumour
US6566332B2 (en) * 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
WO2001053537A2 (en) * 2000-01-24 2001-07-26 Dzgenes, Llc Nitric oxide synthase gene diagnostic polymorphisms
WO2001084148A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20040166491A1 (en) * 2001-08-09 2004-08-26 Henderson Lee A Vhl promoter diagnostic polymorphism
ES2425115T3 (es) * 2001-08-21 2013-10-11 Viiv Healthcare Uk Limited Método de cribado para la reacción de hipersensibilidad a un fármaco
JP2005514010A (ja) * 2001-10-12 2005-05-19 セローノ ジェネティクス インスティテュート ソシエテ アノニム Ｎｇｚｉｐａ、ｎｇｚｉｐｄ、ｐｇｚｉｐａおよびｐｇｚｉｐｄポリヌクレオチドおよびポリペプチド、ならびにその使用
EP1513875A2 (en) * 2002-05-10 2005-03-16 Serono Genetics Institute S.A. Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
WO2004081187A2 (en) 2003-03-10 2004-09-23 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
EP2246444A1 (en) 2004-09-14 2010-11-03 The Regents of the University of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
PL1951738T3 (pl) * 2005-11-25 2012-06-29 Cvie Therapeutics Ltd Nowe formy krystaliczne rostafuroksyny
JP4974091B2 (ja) * 2007-07-06 2012-07-11 独立行政法人放射線医学総合研究所 放射線治療後における泌尿器の晩期有害反応の発症予測用ｄｎａチップ、及びこれを用いた放射線治療後における泌尿器の晩期有害反応の発症予測方法
JP5476536B2 (ja) * 2007-10-03 2014-04-23 独立行政法人放射線医学総合研究所 乳癌の放射線治療による晩期副作用の発症を予測する方法
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
JP2010106007A (ja) 2008-08-14 2010-05-13 Sony Corp 薬剤徐放剤、吸着剤、機能性食品、マスク及び吸着シート
SG2014010912A (en) * 2009-03-23 2014-06-27 Sigma Tau Ind Farmaceuti 5-ß, 14-ß-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEINURIA, GLOMERULOSCLEROSIS AND RENAL FAILURE

Also Published As

Publication number Publication date
SG10201406457VA (en) 2014-11-27
EP2490694A2 (en) 2012-08-29
JP2015128435A (ja) 2015-07-16
EP2490694B1 (en) 2015-09-16
KR20140060323A (ko) 2014-05-19
BR112012009144B8 (pt) 2021-05-25
US20130018024A1 (en) 2013-01-17
SMT201500281B (it) 2016-01-08
ES2551877T3 (es) 2015-11-24
PT2490694E (pt) 2015-12-02
BR112012009144A2 (pt) 2018-10-16
RS54416B1 (en) 2016-04-28
AU2010309921A1 (en) 2012-05-03
SI2490694T1 (sl) 2015-12-31
HRP20151185T1 (hr) 2015-12-04
CA2777310A1 (en) 2011-04-28
WO2011048033A3 (en) 2011-07-14
WO2011048033A2 (en) 2011-04-28
JP2014040418A (ja) 2014-03-06
BR112012009144B1 (pt) 2020-12-01
DK2490694T3 (en) 2015-11-30
KR20170121325A (ko) 2017-11-01
MX2012004559A (es) 2012-12-05
ME02347B (me) 2016-06-20
JP2013508329A (ja) 2013-03-07
JP6130268B2 (ja) 2017-05-17
IL219173A0 (en) 2012-06-28
KR102053470B1 (ko) 2019-12-06
CA2777310C (en) 2018-08-28
US9408854B2 (en) 2016-08-09
KR20120093297A (ko) 2012-08-22
IL219173A (en) 2017-08-31
PL2490694T3 (pl) 2016-02-29
CN102695512B (zh) 2017-05-10
HUE028075T2 (en) 2016-11-28
CN102695512A (zh) 2012-09-26
AU2010309921B2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
EA201270574A1 (ru) Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
ATE418346T1 (de) Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
NZ607996A (en) Substituted nucleotide analogs
EP2548950A3 (en) Reprogramming T cells and hematopoietic cells
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
UA115761C2 (uk) Рекомбінантна молекула днк, яка вказує на присутність трансгенного об'єкта сої mon 87708
WO2010034838A3 (en) Antiproliferative compounds
MX2009011064A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
WO2010022897A3 (de) Methoden zur verbesserung des pflanzenwachstums
WO2009090639A3 (en) Sirna compounds and methods of use thereof
WO2008109142A3 (en) Pirna and uses related thereto
PH12012501831B1 (en) Protein ipa1 related to plant architecture, its coding genes and uses
HK1200274A1 (en) Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2014023285A3 (de) Transgene pflanze der art solanum tuberosum mit resistenz gegenüber phytophthora
EP2898923A3 (en) Isoflavones for regulating sirtuin gene expression
MX352195B (es) Genes que proporcionan resistencia al mildiú polvoroso en cucumis melo.
WO2008112898A3 (en) Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
TW200833248A (en) Bisoximes as fungicides
MX2009005875A (es) Sorgo resistente a herbicida de acetolactato sintasa.
UA110021C2 (uk) Спосіб забезпечення принаймні часткової резистентності чи підвищення резистентності у рослини проти ооміцетної інфекції
WO2011154611A3 (en) A method for enhanced protein synthesis
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection
WO2010041827A3 (en) NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME